He Yuan, Liu Yuling, Liu Yu, Wang Jiancheng, Zhang Xuan, Lu Wanliang, Ma Zhizhong, Zhu Xiuan, Zhang Qiang
Department of Ophthalmology, Third Hospital, Peking University, Beijing, Peoples Republic of China.
Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3983-8. doi: 10.1167/iovs.05-1373.
A sustained intraocular level of immunosuppressive drug is desirable for the treatment of uveitis and other intraocular immune disorders. The objective of the present investigation was to assess the suitability of cyclosporine-loaded poly(lactic-co-glycolic acid) microspheres (CyS-PLGA-MS) to achieve this goal.
A solvent-evaporation method was used in the preparation of CyS-PLGA-MS. These microspheres were characterized for drug loading, entrapment efficiency, and in vitro release by high-performance liquid chromatography, particle size by phase-contrast light microscopy and surface morphology by scanning electron microscopy. The 3H-CyS-PLGA-MS suspension was injected into the vitreous body of healthy rabbits, and the concentration of cyclosporine in various ocular tissues and blood at predetermined intervals was measured by a scintillation counting technique and the pharmacokinetic parameters were calculated. Intravitreous administration of 3H-CyS solution was conducted as the control.
The CyS-PLGA-MS was produced, with drug-loading ranging from 11% to 16% and a high entrapment efficiency from 86% to 98%. Microspheres were discrete, spherical particles with a diameter of approximately 50 microm. The CyS was constantly and slowly released from microspheres in the in vitro release experiment. Compared with CyS solution, microspheres prolonged the release of CyS and maintained therapeutic CyS concentrations for at least 65 days in disease-related tissues such as the choroid-retina and iris-ciliary body. The percentage of CyS released in vitro correlated well with the CyS distribution rate in vivo.
CyS-PLGA-MS, displaying sustained intraocular release of CyS and showing advantages over CyS solution, may meet clinical needs more efficiently.
对于葡萄膜炎和其他眼内免疫性疾病的治疗,需要眼内持续保持免疫抑制药物的浓度。本研究的目的是评估载有环孢素的聚乳酸 - 乙醇酸共聚物微球(CyS - PLGA - MS)实现这一目标的适用性。
采用溶剂蒸发法制备CyS - PLGA - MS。通过高效液相色谱法对这些微球进行载药量、包封率和体外释放特性的表征,通过相差显微镜观察粒径,通过扫描电子显微镜观察表面形态。将³H - CyS - PLGA - MS混悬液注入健康兔的玻璃体,采用闪烁计数技术在预定时间间隔测量各眼组织和血液中环孢素的浓度,并计算药代动力学参数。以玻璃体腔内注射³H - CyS溶液作为对照。
制备出了CyS - PLGA - MS,载药量范围为11%至16%,包封率高达86%至98%。微球为离散的球形颗粒,直径约为50微米。在体外释放实验中,环孢素从微球中持续缓慢释放。与环孢素溶液相比,微球延长了环孢素的释放时间,并在脉络膜 - 视网膜和虹膜 - 睫状体等疾病相关组织中至少65天维持治疗性环孢素浓度。环孢素的体外释放百分比与体内环孢素分布率具有良好的相关性。
CyS - PLGA - MS能在眼内持续释放环孢素,且相较于环孢素溶液具有优势,可能更有效地满足临床需求。